Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.450, 2004-01, pp. : 7-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
PEG IFN- -2a beats conventional therapy in hepatitis C
Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. :
Access to resources
Recommend
PEG IFN- -2b + weight-based ribavirin best value in hep C
Inpharma, Vol. 1, Iss. 1386, 2003-01 ,pp. :
PEG IFN- -2a improves QOL in hepatitis C
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. :
Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :
PEG IFN- -2a flies ahead in chronic hepatitis C
Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. :